Ernie Zuraida Ali

Ernie Zuraida Ali

Auto-generated profile, based on publicly available information

Ernie Zuraida Ali

Inborn Error of Metabolism and Genetic Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2015 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
EAErnie Zuraida Ali
Ernie Zuraida Ali
MKMohd Khairul Nizam Mohd Khalid
Mohd Khairul Nizam Mohd Khalid
ZYZabedah Md Yunus
Zabedah Md Yunus
YYYusnita Yakob
Yusnita Yakob
CCChen Bee Chin
Chen Bee Chin
LNLock-Hock Ngu
Lock-Hock Ngu

4 August 2023 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MCMei-Yan Chan
Mei-Yan Chan
JJJulaina Abdul Jalil
Julaina Abdul Jalil
YYYusnita Yakob
Yusnita Yakob
SWSiti Aishah Abdul Wahab
Siti Aishah Abdul Wahab
EAErnie Zuraida Ali
Ernie Zuraida Ali
LNLock-Hock Ngu
Lock-Hock Ngu
Background: Pompe disease is a rare glycogen storage disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to glycogen deposition in multiple tissues. Infantile-onset Pompe disease (IOPD) patients present within the first year of life with profound hypotonia and hypertrophic cardiomyopathy. Treatment with enzyme replacement therapy (ERT) has significantly improved survival for this otherwise lethal disorder. This study aims to describe the clinical and molecular spectrum of Malaysian IOPD patients, and to analyze their long term treatment outcomes. Methods: Seventeen patients diagnosed with IOPD between 2000 and 2020 were included in this retrospective cohort study. Clinical and biochemical data were collated and analyzed using descriptive statistics. GAA enzyme levels were performed on dried blood spots. Molecular analysis of the GAA gene was performed by polymerase chain reaction and Sanger sequencing. Structural modelling was used to predict the effect of the novel mutations on enzyme structure. Results: Our cohort had a median age of presentation of 3 months and median age of diagnosis of 6 months. Presenting features were hypertrophic cardiomyopathy (100%), respiratory insufficiency (94%), hypotonia (88%), failure to thrive (82%), feeding difficulties (76%), and hepatomegaly (76%). Fourteen different mutations in the GAA gene were identified, with three novel mutations, c.1552-14_1552-1del, exons 2–3 deletion and exons 6–10 deletion. The most common mutation identified was c.1935C > A p.(D645E), with an allele frequency of 33%. Sixteen patients received ERT at the median age of 7 months. Overall survival was 29%. Mean age of death was 17.5 months. Our longest surviving patient has atypical IOPD and is currently 20 years old. Conclusions: This is the first study to analyze the genotype and phenotype of Malaysian IOPD patients, and has identified the c.1935C > A p.(D645E) as the most common mutation. The three novel mutations reported in this study expands the mutation spectrum for IOPD. Our low survival rate underscores the importance of early diagnosis and treatment in achieving better treatment outcomes.

1 August 2017
Verified
Journal Article
Closed access
EAE Z Ali
E Z Ali
YYY Yakob
Y Yakob
NDN Desa
N Desa
TIT Ishak
T Ishak
ZZZ Zakaria
Z Zakaria
WKW T Keng
W T Keng

5 August 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
EAErnie Zuraida Ali
Ernie Zuraida Ali
YZYuslina Zakaria
Yuslina Zakaria
MRMohd Amran Mohd Radzi
Mohd Amran Mohd Radzi
LNLock-Hock Ngu
Lock-Hock Ngu
Siti Azma JusohSiti Azma Jusoh
Siti Azma Jusoh
Ornithine transcarbamylase deficiency (OTCD), an X-linked disorder that results from mutations in the OTC gene, causes hyperammonemia and leads to various clinical manifestations. Mutations occurring close to the catalytic site of OTCase can cause severe OTCD phenotypes compared with those caused by mutations occurring on the surface of this protein. In this study, we report two novel OTC missense mutations, Q171H and N199H, found in Malaysian patients. Q171H and N199H caused neonatal onset OTCD in a male and late OTCD in a female, respectively. In silico predictions and molecular docking were performed to examine the effect of these novel mutations, and the results were compared with other 30 known OTC mutations. In silico servers predicted that Q171H and N199H, as well as 30 known missense mutations, led to the development of OTCD. Docking analysis indicated that N-(phosphonoacetyl)-L-ornithine (PALO) was bound to the catalytic site of OTCase mutant structure with minimal conformational changes. However, the mutations disrupted interatomic interactions in the catalytic site. Therefore, depending on the severity of disruption occurring at the catalytic site, the mutation may affect the efficiency of mechanism and functions of OTCase.

26 September 2025 in Medicine
Verified
Journal Article
Open access
NANUR AISYAH AZIZ
NUR AISYAH AZIZ
EAErnie Zuraida Ali
Ernie Zuraida Ali
MKMohd Khairul Nizam Mohd Khalid
Mohd Khairul Nizam Mohd Khalid
NANursaedah Abdullah Aziz
Nursaedah Abdullah Aziz
NONorodiyah Othman
Norodiyah Othman
KBKhairul Azhar Abu Bakar
Khairul Azhar Abu Bakar
Rationale: Hemoglobin E beta-thalassemia (HbE-BT) is a prevalent and genetically diverse inherited hemoglobin disorder in Malaysia. While most cases are attributed to known genetic variants, discovering novel mutations is essential for understanding their wide-ranging clinical presentations and underlying genetic heterogeneity. Patient concerns: We present the case of a Malay male patient with an intermediate phenotype of HbE-BT whose clinical course was marked by a progression to a transfusion-dependent status, a change triggered by an acute febrile illness. The case highlights the complex challenges of long-term management, including a high risk of iron overload and the significant morbidity and mortality associated with postsplenectomy infections. Diagnoses: The patient was referred for a comprehensive DNA analysis of thalassemia syndromes. Full blood count showed hypochromic microcytic anemia (hemoglobin 7.90 g/dL, mean corpuscular volume 66.10 fL). Hemoglobin analysis via capillary electrophoresis revealed a characteristic pattern of HbA (49.1%), HbE (20.6%), and HbF (27.0%). Sanger sequencing subsequently confirmed a compound heterozygous state of HBB:c.79G>A (HbE) and a novel frameshift mutation at codon 124 of the beta-globin gene (HBB:c.375_376delAC). Predictive computational tools further supported the pathogenicity of this new variant, and its data have been submitted to the ITHANET database (IthaID: 4155). Interventions: Initially, the patient’s condition was managed with nutritional supplements and intermittent blood transfusions. Following an acute febrile episode at age 26, his clinical condition worsened, necessitating regular monthly blood transfusions to manage severe anemia. He also received subcutaneous chelation therapy to address severe hepatic iron overload. At age 36, he underwent a splenectomy to reduce his transfusion requirements. Outcomes: Despite these interventions, the patient passed away at the age of 37 from septic shock and multiorgan failure. This outcome occurred a year after his splenectomy and underscores the critical risk of overwhelming postsplenectomy infection, a significant complication in splenectomized thalassemia patients. Lessons: Identifying this novel compound heterozygosity contributes to our understanding of the genetic landscape of HbE-BT in Malaysia. This case reinforces the importance of comprehensive molecular analysis for accurate diagnosis, and it has important implications for improving long-term management and genetic counseling strategies for patients with thalassemia syndromes.